MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$50,645K
(-42.46%↓ Y/Y)
Proceeds from employee
stock purchase plan
$780K
(192.13%↑ Y/Y)
Proceeds from exercise of
stock options
$473K
(1870.83%↑ Y/Y)
Net cash provided by
(used in) investing...
$4,854K
(-83.15%↓ Y/Y)
Net cash provided by
financing activities
$1,200K
(943.48%↑ Y/Y)
Canceled cashflow
$45,791K
Canceled cashflow
$53K
Net decrease in cash
and cash...
-$5,447K
(-369.97%↓ Y/Y)
Canceled cashflow
$6,054K
Stock-based compensation
$3,840K
(-23.00%↓ Y/Y)
Accrued expenses
$768K
(125.91%↑ Y/Y)
Prepaid expenses and
other current assets
-$611K
(-123.81%↓ Y/Y)
Noncash operating lease
expense
$521K
(13.26%↑ Y/Y)
Depreciation and
amortization
$134K
(-14.65%↓ Y/Y)
Purchases of marketable
securities
$45,785K
(-22.57%↓ Y/Y)
Purchase of property and
equipment
$6K
(-93.41%↓ Y/Y)
Payments of deferred
offering costs
$53K
(-69.89%↓ Y/Y)
Net cash used in
operating activities
-$11,501K
(61.76%↑ Y/Y)
Canceled cashflow
$5,874K
Net loss
-$15,154K
(52.69%↑ Y/Y)
Accounts payable
-$990K
(-621.05%↓ Y/Y)
Accretion of
premiums/discounts on marketable...
$851K
(22.98%↑ Y/Y)
Operating lease
liabilities
-$380K
(25.34%↑ Y/Y)
Back
Back
Cash Flow
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)
source: myfinsight.com